4.7 Article

Mitochondrial Fusion, Fission, and Mitophagy in Cardiac Diseases: Challenges and Therapeutic Opportunities

期刊

ANTIOXIDANTS & REDOX SIGNALING
卷 36, 期 13, 页码 844-863

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2021.0145

关键词

mitochondrial dynamics; metabolism; bioenergetic dysfunction; oxidative stress; cardiovascular diseases; therapy

资金

  1. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2019/22204-2, 2018/18627-3, 2019/25049-9, 2013/07937-8, 2015/22814-5]
  2. Conselho Nacional de Pesquisa e Desenvolvimento-Brasil (CNPq)
  3. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) [001]
  4. NIH [R01HL52141]

向作者/读者索取更多资源

Mitochondria are crucial to heart physiology, but accumulation of damaged mitochondria is a characteristic of cardiac diseases. Disruption of quality control systems leads to dysfunctional mitochondria, impaired cardiac bioenergetics, and oxidative stress. Pharmacological tools have emerged to improve the cardiac pool of healthy mitochondria, but clinical studies are needed to validate their effectiveness.
Significance: Mitochondria play a critical role in the physiology of the heart by controlling cardiac metabolism, function, and remodeling. Accumulation of fragmented and damaged mitochondria is a hallmark of cardiac diseases.Recent Advances: Disruption of quality control systems that maintain mitochondrial number, size, and shape through fission/fusion balance and mitophagy results in dysfunctional mitochondria, defective mitochondrial segregation, impaired cardiac bioenergetics, and excessive oxidative stress.Critical Issues: Pharmacological tools that improve the cardiac pool of healthy mitochondria through inhibition of excessive mitochondrial fission, boosting mitochondrial fusion, or increasing the clearance of damaged mitochondria have emerged as promising approaches to improve the prognosis of heart diseases.Future Directions: There is a reasonable amount of preclinical evidence supporting the effectiveness of molecules targeting mitochondrial fission and fusion to treat cardiac diseases. The current and future challenges are turning these lead molecules into treatments. Clinical studies focusing on acute (i.e., myocardial infarction) and chronic (i.e., heart failure) cardiac diseases are needed to validate the effectiveness of such strategies in improving mitochondrial morphology, metabolism, and cardiac function.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据